Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05438420 · ClinicalTrials.gov registry record · Phase 1

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

A Phase 1 study of Gastric Cancer and Cervical Cancer, sponsored by Qurient Co..

Active
Registry status
Phase 1
Development phase
120
Enrollment target
7
Study locations

NCT05438420 is a Phase 1 study of Gastric Cancer and Cervical Cancer that is active but no longer recruiting, run by Qurient Co.. The registered enrollment target is 120 participants, below the 318-participant average among 153 other Gastric Cancer trials with a reported enrollment target (62% lower). The trial reports 7 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05438420, a Phase 1 study of Gastric Cancer and Cervical Cancer, is active but no longer recruiting, sponsored by Qurient Co..

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
120 participants
Enrollment target
7
Study locations

Study Summary

This study is a phase 1B/2 open-label, study to determine safety and preliminary efficacy of Q702 in combination with pembrolizumab in study subjects with advanced esophageal, gastric/GEJ, hepatocellular, and cervical cancers.

Conditions Studied

Gastric Cancer Cervical Cancer Esophageal Cancer Hepatocellular Cancer

Interventions

  • BIOLOGICAL Pembrolizumab
  • DRUG Q702

Study Locations (7)

Other

  • CHA Bundang Medical Center - Seongnam-si
  • Asan Medical Center - Seoul
  • Samsung Medical Center - Seoul
  • Seoul National University Hospital - Seoul
  • Severance Hospital - Seoul

California

  • University of Southern California - Los Angeles

Kentucky

  • Norton Cancer Institute - Louisville

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2023-01-12
Est. Completion 2028-03-30
Phase Phase 1

Sponsor

Qurient Co.

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05438420

The ClinicalTrials.gov registry entry for NCT05438420 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 318-participant average among 153 other Gastric Cancer trials with a reported enrollment target (62% lower). The listed sponsor is Qurient Co., which has 7 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT05438420 reports 7 study locations spanning 3 distinct geographic areas - top geographies include Other, California, Kentucky.

Frequently Asked Questions

What is clinical trial NCT05438420 about?

NCT05438420 is a clinical study titled "Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors". This study is a phase 1B/2 open-label, study to determine safety and preliminary efficacy of Q702 in combination with pembrolizumab in study subjects with advanced esophageal, gastric/GEJ, hepatocellular, and cervical cancers.

What is the current status of trial NCT05438420?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2023-01-12. Estimated completion is 2028-03-30.

What conditions does trial NCT05438420 study?

This clinical trial studies the following conditions: Gastric Cancer, Cervical Cancer, Esophageal Cancer, Hepatocellular Cancer.

What interventions are being tested in trial NCT05438420?

The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Q702 (DRUG).

Who is sponsoring clinical trial NCT05438420?

This trial is sponsored by Qurient Co., which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05438420 being conducted?

This trial has 7 study locations across California, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastric Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gastric Cancer

All registered trials for this condition

Cervical Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.